Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9808472
APP PUB NO 20160038511A1
SERIAL NO

14758938

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITY OF WASHINGTON4311 11TH AVENUE NE SUITE 500 SEATTLE WA 98105-4608

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Corey, Eva Seattle, US 2 12
Ferrante, Karen Boston, US 2 12
Jacoby, Douglas Wellesley, US 3 19
Njar, Vincent C O Glen Burnie, US 17 74
Zoubeidi, Amina Vancouver, CA 7 24

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 7, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 7, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00